Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
Conditions: Recurrent Castration-Sensitive Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer Interventions: Drug: Abiraterone; Drug: Apalutamide; Procedure: Biospecimen Collection; Procedure: Bone Scan; Procedure: Computed Tomography; Drug: Darolutamide; Drug: Degarelix; Drug: Enzalutamide; Drug: Goserelin; Drug: Histrelin; Drug: Leuprolide; Procedure: Magnetic Resonance Imaging; Other: Patient Observation; Procedure: Positron Emission Tomography; Drug: Prednisone; Other: Questionnaire Administration; Drug: Relugolix; Radiation: Stereotactic Body Radiation Therapy; Drug: Triptorelin Sponsors: Mayo Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | CT Scan | Hormones | MRI Scan | PET Scan | Prednisone | Prostate Cancer | Radiation Therapy | Research